Dr. Shaker Dakhil, M.D.
Claim this profileAscension Via Christi Hospitals Wichita
Expert in Parotid Gland Cancer
Expert in Lung Cancer
83 reported clinical trials
170 drugs studied
About Shaker Dakhil, M.D.
Education:
- Earned an MD from St. Joseph University School of Medicine, Beirut, Lebanon, in 1975.
Experience:
- Completed Residency in Internal Medicine at Wayne State University, Detroit, Michigan.
- Undertook a Fellowship in Hematology/Oncology at the University of Michigan.
- Certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.
- President of the Cancer Center of Kansas since 2000 and a Clinical Professor of Medicine at the University of Kansas School of Medicine – Wichita.
- Founder of the Wichita Cancer Foundation and recipient of multiple awards for excellence in oncology.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Shaker Dakhil, M.D. is currently running
Multiple Targeted Therapies
for Meningioma
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting1 award Phase 210 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Shaker Dakhil, M.D.
Clinical Trial Related6 years of experience running clinical trials · Led 83 trials as a Principal Investigator · 28 Active Clinical TrialsTreatments Shaker Dakhil, M.D. has experience with
- Carboplatin
- Cisplatin
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Atezolizumab
Breakdown of trials Shaker Dakhil, M.D. has run
Parotid Gland Cancer
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Shaker Dakhil, M.D. specialize in?
Is Shaker Dakhil, M.D. currently recruiting for clinical trials?
Are there any treatments that Shaker Dakhil, M.D. has studied deeply?
What is the best way to schedule an appointment with Shaker Dakhil, M.D.?
What is the office address of Shaker Dakhil, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.